{
  "id": 10130387,
  "title": "Castle Biosciences CEO sells $512k in stock",
  "url": "https://urgent.news/2026/09/27/castle-biosciences-ceo-sells-512k-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-27T03:46:16.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/castle-biosciences-ceo-sells-512k-in-stock-93CH-4918776"
  },
  "original_language": "en",
  "account": "Derek J. Maetzold, CEO of Castle Biosciences, sold 14,496 shares of the company's stock on September 21, 2026, according to wire reports. The transaction, executed under a pre-approved Rule 10b5-1 plan, amounted to $512,201, with the sales executed at an average price of $35.334 per share. Maetzold personally disposed of 8,580 shares, while 3,198 and 2,718 shares were sold indirectly through trusts established for his descendants and other beneficiaries. The sale coincided with a significant rise in CSTL shares, which have increased by 58% over the past year and 52% in the last six months, currently trading at $35.81. Despite being labeled as overvalued by investing professionals, the CEO clarified that he also repurchased 8,580 shares through stock options, exercising them at $2.39 per share. Following the sale, Maetzold now owns 21,479 shares directly and maintains additional holdings through various trusts. Castle Biosciences recently reported second-quarter results that met market expectations with both profit and revenue surpassing forecasts. The company's adjusted loss per share was 7 cents, compared to the expected 40-cent loss, and revenue reached $103.5 million, exceeding the predicted $86.4 million. The firm also boosted its full-year sales guidance. In response to the positive performance, BTIG upgraded its price target for Castle Biosciences from $40 to $44, maintaining a Buy rating. The company's strong market performance, particularly in the TissueCypher franchise, which saw a 63% year-over-year increase in volumes and 28% growth in the previous quarter, is credited for these achievements.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "OnKure Therapeutics CFO Jason Leverone sells $898 in stock",
        "url": "https://urgent.news/2026/09/27/onkure-therapeutics-cfo-jason-leverone-sells-898-in-stock",
        "published": "2026-09-27T01:31:05.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}